Urinary Tract Infection News and Research

RSS

Urinary tract infections are a serious health problem affecting millions of people each year. Infections of the urinary tract are the second most common type of infection in the body. Urinary tract infections (UTIs) account for about 8.3 million doctor visits each year.* Women are especially prone to UTIs for reasons that are not yet well understood. One woman in five develops a UTI during her lifetime. UTIs in men are not as common as in women but can be very serious when they do occur.

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

Avanir initiates enrollment in AVP-923 Phase II clinical trial for treatment of agitation in AD patients

Avanir Pharmaceuticals, Inc. today announced the enrollment of the first patient in study AVR-131. The study is a Phase II clinical trial investigating the use of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.

5 Sep 2012

FDA approves Novartis’ Exelon Patch to treat mild to moderate AD

The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer's disease.

4 Sep 2012

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen Research & Development, LLC, announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug Application (sNDA) for ZYTIGA (abiraterone acetate) administered in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.

30 Aug 2012

Declining rates of circumcision in US infant males could add billions to health care costs

A team of disease experts and health economists at Johns Hopkins warns that steadily declining rates of U.S. infant male circumcision could add more than $4.4 billion in avoidable health care costs if rates over the next decade drop to levels now seen in Europe.

21 Aug 2012

One-week ciprofloxacin effective for pyelonephritis

Treatment for 7 days with the antibiotic ciprofloxacin is as effective at treating acute pyelonephritis in women as a 14-day regimen of the fluoroquinolone, with a similar safety profile, report Swedish researchers.

17 Aug 2012

Reduce nurses’ burden, reduce in-hospital infections

The rate of “burnout” felt by nurses could be directly related to the rate of hospital-acquired infections via staffing rates, indicate US study results.

13 Aug 2012

Positive results from Acorda post-marketing commitment study of dalfampridine-ER for MS

Acorda Therapeutics, Inc. today announced top line results from a post-marketing commitment study evaluating a 5mg dose of dalfampridine-ER to improve walking in people with multiple sclerosis. The study failed to confirm efficacy of the 5mg dose.

13 Aug 2012

Study gauges depression among spouses of severe-sepsis survivors

Severe sepsis, a body's dangerous defensive response against an infection, not only diminishes the quality of life for patients - it puts their spouses at a greater risk of depression, a joint University of Michigan Health System and University of Washington School of Medicine study shows.

19 Jul 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

Sling device a good shot for vaginal prolapse repair

A midurethral sling device added during surgery for vaginal prolapse repair reduces the risk for postoperative urinary incontinence, research shows.

2 Jul 2012

Astellas Pharma receives FDA approval for Myrbetriq to treat overactive bladder

The U.S. Food and Drug Administration today approved Myrbetriq (mirabegron) to treat adults with overactive bladder, a condition in which the bladder muscle cannot be controlled, squeezes too often or squeezes without warning.

29 Jun 2012

Scoring system identifies appendicitis in pediatric acute abdomen pain

Using a pediatric appendicitis score may help to identify true cases of appendicitis among children who present to emergency departments with acute abdominal pain, researchers report.

26 Jun 2012

Mid-urethral sling may reduce risk of urinary incontinence after surgery

For many adult women, supporting tissues in and around their vagina weaken to the point where the bladder and other organs descend from their normal position, creating a hernia into the vaginal wall known as pelvic organ prolapse. One in five women will undergo surgery to repair such prolapse.

22 Jun 2012

Better care for dual-eligible Medicare-Medicaid patients could reduce hospitalization rates

Providing better care for dual-eligible Medicare-Medicaid patients could significantly reduce hospitalization rates for this population, saving taxpayers between $625 million and $1.9 billion per year, according to a new study by researchers at RTI International and Florida Atlantic University.

15 Jun 2012

Acorda commences AMPYRA clinical study for post-stoke deficits

Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in a proof-of-concept study exploring the use of AMPYRA(dalfampridine) Extended Release Tablets, 10 mg in treating patients who have post-stroke deficits.

13 Jun 2012

Dapagliflozin more effective than sitagliptin for adult patients with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from a Phase 3 clinical study that showed the investigational compound dapagliflozin 10 mg demonstrated significant reductions in blood sugar levels (glycosylated hemoglobin levels, or HbA1c) compared with placebo at 24 weeks when either agent was added to existing sitagliptin therapy (with or without metformin) in adult patients with type 2 diabetes.

11 Jun 2012

Artificial noses could allow quick disease screening and ultimately transform diagnostics

Artificial noses have, until now, been used to detect diseases such as urinary tract infection, Helicobacter pylori, tuberculosis, ear, nose and throat conditions and even lung cancer. They have also been clinically tested for use in continuous monitoring of different disease stages.

7 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

Acorda Therapeutics launches Ampyra Dialogues on World MS Day

Acorda Therapeutics, Inc., makers of Ampyra (dalfampridine), today announced the launch of Ampyra Dialogues, the first-ever online talk show where patients and medical experts talk about how walking problems affect people living with MS.

31 May 2012